Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
June 20, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...